Superworth

Staar Surgical PE ratio STAA

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Nov 2, 2026
356×
8-year median
144×
Against its 8-year history
87th
percentile: 0 is its lowest day, 100 its highest
8-year range
34.9× to 499×
Peer median
29.6×

Staar Surgical's PE ratio is 356× as of Nov 2, 2026: a share price of $24.94 against $0.07 of earnings per share over the last twelve months.

That is above its 8-year median of 144×, higher than on 87% of days in the last 8 years.

Over that time it ranged from 34.9× in Feb 2025 to 499× in Aug 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 29.6×.

PE ratio over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far356×293×374×
202538.3×34.9×55.8×
202455.0×55.0×154×
202380.0×72.6×105×
202263.9×63.7×180×
2021198×194×481×
2020417×87.0×469×
2019203×160×455×
2018391×371×499×
2017n/m a value too high to mean anything
2016n/m a value too high to mean anything
2015n/m a value too high to mean anything
2014n/m a value too high to mean anything
2013n/m a value too high to mean anything
2012213×191×373×

Against its peers

Companies in Medical - Instruments & Supplies nearest Staar Surgical's size, closest first, today.

CompanyPE ratio
STAAStaar Surgical356×
CDRECadre38.9×
EYENational Vision28.1×
BVSBioventus17.1×
IARTIntegra Lifesciences80.1×
IRMDIradimed42.5×
LMATLemaitre Vascular28.5×
INSPInspire Medical Systems14.5×
UFPTUFP Technologies30.6×
MOVMovado17.7×
WRBYWarby Parker341×
Peer median29.6×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Staar Surgical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.